Suzetrigine: A Newly FDA-Approved Non-Opioid Treatment Option for Management of Moderate to Severe Acute Pain.

Alexandra R Rola, Jared R Bagley, Emily E Leppien

Abstract readReview

In one paragraph

Review in Innovations in clinical neuroscience. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alexandra R RolaAll authors are with the Binghamton University School of Pharmacy and Pharmaceutical Sciences, Johnson City, New York.

Jared R BagleyAll authors are with the Binghamton University School of Pharmacy and Pharmaceutical Sciences, Johnson City, New York.

Emily E LeppienAll authors are with the Binghamton University School of Pharmacy and Pharmaceutical Sciences, Johnson City, New York.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe objective of this study was to review the characteristics, efficacy, and safety of suzetrigine in the treatment of acute pain.

methodsLiterature was identified using PubMed and clinicaltrials.gov. Search terms included suzetrigine, Journvax, and VX-548, with further limitation to those published in English. Articles selected for inclusion were trials evaluating the safety or efficacy of suzetrigine.

resultsSuzetrigine was evaluated for the treatment of moderate-to-severe acute pain in 2 published phase 2 trials and in 3 unpublished phase 3 trials. All studies report a statistically significant reduction in pain scores. High-dose suzetrigine showed statistically and clinically significant pain reduction vs placebo in abdominoplasty 48.4 (95% confidence interval [CI]: 33.6-63.1;

conclusionThe recent United States Food and Drug Administration approval of suzetrigine introduces a novel class of analgesics; however, its clinical impact has yet to be defined.

Indexed as

acute painJournavxpostoperative painsuzetrigineVX-548

Identifiers

PMID42762048

PMCPMC13588656

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.